Accuray Incorporated ( ARAY Quick Quote ARAY - Free Report) reported a loss of 4 cents per share for the fourth quarter of fiscal 2022, narrower than the loss of 12 cents per share in the year-ago period. The loss per share was also narrower than the Zacks Consensus Estimate of a loss of 6 cents per share.
Our projection of loss per share was 6 cents.
Full-year loss per share was at 6 cents, narrower than the loss of 7 cents at the end of fiscal 2021. The metric was also narrower than the Zacks Consensus Estimate of a loss of 9 cents per share.
Our projection of loss per share for fiscal 2022 was 8 cents.
Revenues in Detail
Accuray registered revenues of $110 million in the fiscal 2022 fourth quarter, down 0.8% year over year. The figure beat the Zacks Consensus Estimate by 4.9%.
The second-quarter revenue compares to our estimate of $104 million.
Full-year revenues were $429.9 million, reflecting an 8.5% improvement from the comparable fiscal 2021 period. The metric topped the Zacks Consensus Estimate by 1.2%.
The fiscal full-year revenue compares to our estimate of $423.9 million.
Accuray derives revenues from two sources — Products and Services.
In the fiscal fourth quarter, Product revenues improved 3.4% from the year-ago quarter to $58 million. CyberKnife accounted for around 35% of revenue unit volume in the quarter, whereas the TomoTherapy platform accounted for the remaining 65%.
This figure compares to our Product revenues’ Q4 projection of $52.7 million.
Services revenues fell 5.1% from the year-ago quarter to $51.9 million, primarily due to unfavorable foreign exchange impacts.
This figure compares to our Services revenues’ Q4 projection of $51.3 million.
Gross orders totaled $88.3 million, down 21.6% year over year. This figure compares to our gross orders’ Q4 projection of $115.3 million.
In the quarter under review, Accuray’s gross profit fell 1.6% to $43 million. Gross margin contracted 32 basis points (bps) to 39.1%.
We had projected 37.9% of gross margin for Q4.
Selling and marketing expenses rose 10.4% to $14.4 million. Research and development expenses fell 5.1% year over year to $14.6 million, while general and administrative expenses went up 7.3% year over year to $12 million. Total operating expenses of $40.9 million rose 3.5% year over year.
Total operating profit was $2 million, reflecting a 50.6% decline from the prior-year quarter. Operating margin in the fiscal fourth quarter contracted by 187 bps to 1.9%.
We had projected 0.4% of operating margin for Q4.
Accuray exited fiscal 2022 with cash and cash equivalents of $88.7 million compared with $116.4 million at the end of fiscal 2021.
Total debt (including short-term debt) at the end of fiscal 2022 was $180.5 million compared with $173.8 million at the end of fiscal 2021.
Accuray has initiated its outlook for fiscal 2023 based on current expectations.
The company expect its fiscal year revenues to be $447 million-$455 million, reflecting a year-over-year growth in the range of 4-6%. The Zacks Consensus Estimate for the same is pegged at $450.5 million.
Accuray exited the fiscal fourth quarter of 2022 with better-than-expected results. The year-over-year uptick in Product revenues is encouraging. Continued strong demand for the ClearRT Helical kVCT Imaging for the Radixact System and VOLO Ultra enhancement to the Accuray Precision treatment planning system for the Radixact System and CyberKnife S7 platform are impressive. Favorable real-world data and clinical studies regarding Accuray’s CyberKnife System raises optimism regarding the stock. Accuray’s collaboration with Limbus AI Inc. to enhance Accuray’s adaptive radiotherapy capabilities (in June) is another highlight during the reported quarter.
However, the company’s year-over-year decline in the overall top line and Services revenues is disappointing. The decline in gross orders is also worrying. Contraction of both margins also does not bode well.
Zacks Rank and Key Picks
Accuray currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are
Quest Diagnostics Incorporated ( DGX Quick Quote DGX - Free Report) , AMN Healthcare Services, Inc. ( AMN Quick Quote AMN - Free Report) and Zimmer Biomet Holdings, Inc. ( ZBH Quick Quote ZBH - Free Report) .
Quest Diagnostics, carrying a Zacks Rank #2 (Buy), reported second-quarter 2022 adjusted EPS of $2.36, which beat the Zacks Consensus Estimate by 9.8%. Revenues of $2.45 billion outpaced the consensus mark by 7.5%. You can see
the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Quest Diagnostics has an earnings yield of 6.8% compared with the industry’s 3.8%. DGX’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average being 12.1%.
AMN Healthcare, sporting a Zacks Rank #1, reported second-quarter 2022 adjusted EPS of $3.31, which beat the Zacks Consensus Estimate by 11.8%. Revenues of $1.43 billion outpaced the consensus mark by 4.8%.
AMN Healthcare has an estimated long-term growth rate of 3.2%. AMN’s earnings surpassed estimates in all the trailing four quarters, the average being 15.7%.
Zimmer Biomet reported second-quarter 2022 adjusted EPS of $1.82, which surpassed the Zacks Consensus Estimate by 11.7%. Second-quarter revenues of $1.78 billion outpaced the Zacks Consensus Estimate by 3.5%. It currently has a Zacks Rank #2.
Zimmer Biomet has an estimated long-term growth rate of 5%. ZBH’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average being 7.4%.